The clinical benefits of IDegLira in DUAL VII were achieved while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy - Media Centre | EASD
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in
In a showdown with Sanofi, FDA questions Novo's PhIII data for IDegLira | Fierce Biotech
Mixed reaction to Novo Nordisk obesity trial - PMLiVE
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
Novo Nordisk and Sanofi diabetes combo drugs receive US recommendation
Overview of studies design evaluating the efficacy of iDegLira and... | Download Scientific Diagram
ADA 2014: New data on Novo Nordisk's IDegLira and Victoza
Combination of Novo Nordisk's Insulin degludec and Victoza Provides Synergistic Benefits in Late-Stage Trial
Liraglutide Insulin Degludec Ideglira Xultophy (Novo Nordisk) | Bioz | Ratings For Life-Science Research
US approval for Novo Nordisk's Xultophy/IDegLira as diabetes battle hots up
Novo Nordisk's GLP-1/insulin combination, Xultophy, Moves One Step Closer to Approval in Europe
Frontiers | Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting
Peter Falck Christens, Manager Biostatistics IdegLira, (Novo Nordisk) — Ministry of Music
Positive Phase 3b study resutls for Xultophy announced
Novo Nordisk debuts diabetes combo in Mexico - PMLiVE
Novo Nordisk invests $60 million in expansion of Kalundborg site
Xultophy® 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
Novel insulin/GLP-1 combo succeeds in phase III trial | MDedge Endocrinology
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes - ScienceDirect
Physicians' real-world experience with IDegLira: results of a European survey | BMJ Open Diabetes Research & Care
IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUAL V - Media Centre | EASD
Switching to a fixed-ratio combination of insulin degludec/liraglutide ( IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the
